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for the period 2002–2005, for the 180 most selling substances
were used to calculate a chain price index. A regression model
was used to estimate the effects of analog substitution, i.e
switches from one substance to another of the same class, for 
5 major products whose patent expired during the period.
RESULTS: The general price level of pharmaceuticals has fallen
15% during the period and off-patent drugs have experienced a
40% fall in price level. In addition to the direct effect on prices
of a substance due to generic competition, there has also been
analog substitution effect from patented drugs to off-patent
drugs. For two groups of pharmaceuticals, statins and PPIs, there
were signiﬁcant substitution effects between substances due to
the changes in relative prices. CONCLUSIONS: Generic substi-
tution in Sweden has been effective in reducing prices of off-
patent pharmaceuticals. Generic substitution has also had more
farreaching effects than what has been previously believed. There
has been a move from patented to off-patent products within the
same therapeutic area.
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OBJECTIVE: Hungary’s accession to the European Union in
May 2004 compelled reconsideration of the social insurance
inclusion of pharmaceutical products. The Ofﬁce of Health Tech-
nology Assessment (HTA) of the National Institute for Strategic
Health Research was formed in 2004 with the aim of establish-
ing an independent institution to support decision-makers in
their rational use of health care resources. METHODS: The
Ofﬁce provides an organisational framework for the technology
assessment that forms the basis for the medicine subsidy
approval policy of the National Health Insurance Fund, and per-
forms the related medical and economic assessment duties. The
National Health Insurance Fund makes decisions regarding the
granting of subsidies for medicines, based on the ﬁndings pre-
sented by the Ofﬁce of HTA, which X determines the profes-
sional guidelines for analysing health technology, coordinates the
assessment of new and existing technologies, and issues instruc-
tions for the use of individual technologies X provides reliable
and undistorted information for the appraisal of individual pro-
cedures, comparing them with alternative opportunities for the
use of resources based on a combination of clinical evidence, efﬁ-
cacy and cost-effectiveness factors, X facilitates the appropriate
use of cost-effective health care technologies, and provides
support for decision-makers. RESULTS: The majority of appli-
cations were related to anti-tumour drugs and products designed
to treat diseases of the cardiovascular or central nervous system.
The Ofﬁce also performs problem-oriented comparative exami-
nations, such as the comprehensive policy study of Positron
Emission Tomography (PET) and Gamma-knife Surgery, Drug-
eluting Coronary Stents, etc. CONCLUSION: In the initial
period, staff at the Ofﬁce of Health Technology Assessment
focused primarily on assessments of medicines to determine their
eligibility for social insurance funding, but as the new institu-
tional structure becomes more ﬁrmly established, it is increas-
ingly able to perform thorough, comprehensive assessments of
other health technologies.
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OBJECTIVES: Anwendungsbeobachtungen (AWBs) are a
common type of postmarketing surveillance studies in Germany.
They provide information about medical beneﬁt, safety, and
effectiveness of drugs in daily practice and can support reim-
bursement decisions. As practice based research gains in impor-
tance the scientiﬁc quality of AWBs was evaluated. METHODS:
The German drug law demands the reporting of AWBs to
NASHIP. In the examined six-month period (July to December
2005), 453 AWBs were announced to NASHIP. Onehun-
dredeighteen were announced for the ﬁrst time, the others were
supplementary information to ongoing AWBs. AWB-conducting
companies were asked for more detailed information and AWBs
designs were analysed by a validated data entry form that was
based on recommendations of the Federal Institute for Drugs and
Medical Devices for the conduct of AWBs. RESULTS: One
hundred-eight AWBs included statements about goals: 46%
listed drug utilisation, 87% safety, 68% effectiveness and 24%
QoL. Only a third of AWBs chose a suitable design, basically
those that examined safety and drug-utilisation. Only 10% were
comparative. Most evaluated drugs were high-priced up to costs
of Euro 4500 per prescription. Almost 50% of all drugs had
obtained marketing authorisation during the last ﬁve years.
Median observation time per patient was 140 days. Only 19%
of all AWBs mentioned a planned publication of results explic-
itly. CONCLUSIONS: This study showed the very heterogeneous
quality of AWBs in Germany. In most AWBs the marketing aspect
dominated obviously and they were not suitable for reimburse-
ment decisions on the basis of the price-beneﬁt ratio.
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OBJECTIVES: The aim of the study was to determine the cost-
effectiveness ratio of professionals in ﬁve Spanish primary care
teams (Spanish “EAPs”) on the basis of Adjusted Clinical Groups
(ACGs). METHODS: Retrospective descriptive study. We
included all patients attended by ﬁve EAPs in 2004. Principal
measurements: age, sex, consultation episodes/reasons, total
cost/expense (semi-ﬁxed: personnel, procurement; variable:
pharmaceutical expense, referrals, tests), department, centre,
physician in charge (Spanish “UBA”—basic care unit) and a
qualitative synthetic index (Spanish “ISC”) drawn from 36
process and outcome indicators relating to health care practice.
Every patient was assigned to an exclusive ACG/category. We
produced the adjusted efﬁciency index (Spanish “IE”) indicating
relative efﬁciency with reference to a standard (observed/
expected; grouper-6.0; Johns Hopkins University) and the 
ISC for each centre and UBA. We analysed the correlation of IE
and ISC (Spearman’s rank correlation) and a range of indirect
standardisations to adjust the results. Statistical signiﬁcance 
p < 0.05. RESULTS: We studied 81,085 patients (use intensity
76.9%), with a mean of 5.0 ± 3.6 and 8.0 ± 8.2 visits per patient
per year. The total cost per attended patient per year was 
340 euros (reference average relative weight). Pharmaceutical
prescription costs accounted for more than 60%. The efﬁciency
indices (IE) of the centres were: 0.92, 0.94, 0.95, 1.06, and 1.06
(p = 0.000). The qualitative synthetic indices (ISC) were: 68.9%,
66.1%, 45.8%, 43.4%, and 31.6% (p = 0.000). An inverse cor-
relation was found between IE and ISC (p < 0.001; R2 = 36%).
The explanatory power of the classiﬁcation was 53%. CON-
